Napazimone

It's only fair to share...

Napazimone

CAS 1800405-30-4

MF C14H12N2O2 MW240.26 g/mol

2-(propan-2-yl)-1H-naphtho[1,2-d]imidazole-4,5-dione
NAD(P)H dehydrogenase [quinone] 1 (NQO1) activator, KL 1333, KL-1333, NA2ZOL5UGM

Napazimone (also known as KL1333) is an investigational small molecule drug currently being developed for the treatment of primary mitochondrial disease. It is an orally available modulator that aims to improve energy production in patients with rare genetic conditions affecting mitochondrial DNA (mtDNA).

Mechanism of Action

According to ProbeChem.com and Synapse, Napazimone works through the following mechanisms:

NAD+ Modulation: It increases intracellular levels of NAD+ by reacting with the enzyme NQO1, which helps shift the NAD+/NADH ratio.
Signaling Pathway Activation: The drug activates the SIRT1/AMPK/PGC-1α signaling network, which is critical for regulating mitochondrial biogenesis and function.
Mitochondrial Improvement: In laboratory studies using MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) fibroblasts, the compound increased ATP levels and decreased harmful reactive oxygen species (ROS) and lactate.

Clinical Development and Indications

Napazimone is being developed by Pharming Group for adult patients with primary mitochondrial disease, a condition often characterized by extreme fatigue and muscle weakness.

Trial Status: As of early 2026, the drug is in Phase II/III clinical trials.
FALCON Trial: A pivotal study known as the FALCON trial is currently ongoing, with a data readout expected in 2027.
Potential Indications: It is primarily being investigated for mtDNA-driven mitochondrial diseases and has shown potential in research for protecting against hearing loss (ototoxicity) caused by chemotherapy drugs like cisplatin.

Chemical Properties

The following specifications are provided by Inxight Drugs and PubChem:

Chemical Name: 2-isopropyl-3H-naphtho[1, 2-d]imidazole-4,5-dione.
Molecular Formula: C14H12N2O2.
Molecular Weight: 240.26 g/mol.

Would you like more information on the FALCON clinical trial or details about the mitochondrial diseases Napazimone is intended to treat?

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial DiseaseCTID: NCT05650229Phase: Phase 2Status: RecruitingDate: 2025-10-09
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial DiseaseCTID: NCT03888716Phase: Phase 1Status: CompletedDate: 2021-10-20
Drug-drug Interaction Study of KL1333 in Healthy SubjectsCTID: NCT04643249Phase: Phase 1Status: CompletedDate: 2021-10-20
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male VolunteersCTID: NCT03056209Phase: Phase 1Status: CompletedDate: 2018-04-27

SYN

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015102371&_cid=P21-MLPZ73-91594-1

Example 1 [Synthesis of Compound 1]: 2-isopropyl-lH-naphtho [2, l-d] imidazole-4,5-dione

1) IStep Pyridine (5 ml) is added to compound A (4-amino-1 -naphthol hydrochloride, 500 mg, 2.55 mmol), and the ice bath is dehydrated and cooled. This is followed by dropwise isobutyric anhydride (1.7 ml, 10.2 mmol). The reaction product is stirred for 2.5 hours at the same temperature. The reactants are quenched with methanol and concentrated under reduced pressure to remove any pyridine. After adding EA and distilled water, adjust pH to about 6.5 with 1 N HC1 solution, and then wash the organic layer several times to remove the remaining pyridine. The organic layer was dried over Na ₂ S0 ₄ , filtered and concentrated under reduced pressure. The concentrated reaction product was purified by silica gel column chromatography to obtain compound B-1 (686 mg, 90%).

2) 2Step

Add Acetic anhydride (3 ml) to Compound B-1 (300 mg, 1.00 mmol) and dropwise fuming nitric acid (0.20 ml, 2.00 mmol) at 0 ° C. The reaction product is stirred for 1 hour and then filtered. The filtered solid is then washed several times with Hexane with compound B-2. compound B-2 (217 mg, 63%).

1 H NMR (300 MHz, Acetone-d ₆ ) δ 9.55 (s, IH), 8.33 (d, J = 6.6 Hz, IH), 8.06 (d, J = 6.2 Hz, IH), 7.86 (s, IH), 7.81-7.73 (m, 2H), 3.16-3.07 (m, IH), 2.96-2.87 (m, IH), 1.41 (d, J-7.0 Hz, 6H), 1.25 (d, J-7.0 Hz, 6H)

3) 3 Step

Compound B-2 (500 mg, 1.45 mmol) is dissolved in ethanol (5 ml), and then Pd / C (50 mg) and Hydrazine (0.29 ml, 5.81 mmol) are added in this order. The reaction is allowed to react for 1 hour at 70 degrees. The reaction product is cooled to room temperature and the Pelite / C is removed by celite filter. The filtrate is concentrated under reduced pressure and purified by silica gel column chromatography to obtain compound B-3 (232 mg, 51%).

MR NMR (300 MHz, CD ₃ OD) δ 8.02 (d, J = 8.4 Hz, IH), 7.50 (d, J = 8.0 Hz, IH), 7.35 (t, J-8.0 Hz, IH), 7.13 (t, J = 8.1 Hz, IH), 6.47 (s, IH), 2.85-2.83 (m, IH), 1.31 (d, J = 7.0 Hz, 6H)

LC-MS m / z 245.1 (M + l)

4) 4Step

Acetic acid (15 ml) is added to Compound B-3 (700 mg, 2.86 mmol), and the mixture is stirred and refluxed for 3 hours. Acetic acid is removed by concentration under reduced pressure, and purified by silica gel column chromatography to obtain compound B-4 (575 mg, 89%) ¾-

MR NMR (300 MHz, CD ₃ OD) δ 8.30 (d, J = 8.4 Hz, 2H), 7.60 (t, J = 8.0 Hz, IH), 7.47

(t, J = 8.1 Hz, IH), 6.99 (s, IH), 3.35-3.28 (m, IH), 1.46 (d, J = 7.0 Hz, 6H)

LC-MS m / z 227.0 (M + l)

5) 5 Step

Dissolve DMF (2.5 ml) in Compound B-4 (50 mg, 0.22 mmol), and add IBX (159 mg, 0.26 mmol). The reaction is reacted at room temperature for 1 hour. After adding EA, the organic layer is washed with NaHC0 ₃ saturated aqueous solution. The separated organic layer was dried over MgS0 ₄ and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to obtain compound B-5 (47 mg, 89%).

1 H NM (300 MHz, CDC1 ₃ ) δ 9.96 (NH, s, IH), 8.06 (d, J = 7.7 Hz, IH), 7.99 (d, J = 7.7 Hz, IH), 7.65 (t, J = 7.7 Hz, IH), 7.44 (t, J = 7.7 Hz, IH), 3.26-3.17 (m, IH), 1.45 (d, j = 7.0 Hz, 6H)

PAT

1,2-naphthoquinone based derivative and method of preparing the same

Publication Number: US-10766882-B2

Priority Date: 2013-12-30

Grant Date: 2020-09-08